Who is sponsoring NCT06888024?

NCT06888024 is sponsored by Ningcheng Peter Li.

What drugs are being tested in NCT06888024?

Interventions in NCT06888024: non-contrast enhanced abdomen and pelvis MRI.

What condition does NCT06888024 study?

NCT06888024 studies May-Thurner Syndrome, Iliac Venous Compression.

Is NCT06888024 still recruiting?

NCT06888024 is currently recruiting now. Last updated 24 September 2025.

Last reviewed 2025-09-24 · How we verify

NCT06888024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pelvic Vein Quantitative Flow Characterization Using 2D and 4D Flow MRI

Recruiting now NA Last updated 24 September 2025

What this trial tests

NA trial testing non-contrast enhanced abdomen and pelvis MRI in May-Thurner Syndrome in 15 participants. Currently enrolling.

Timeline

1 April 2025

Primary endpoint
1 January 2027

1 January 2027

Quick facts

Lead sponsor	Ningcheng Peter Li
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	15
Start date	1 April 2025
Primary completion	1 January 2027
Estimated completion	1 January 2027
Sites	1 location across United States

Drugs / interventions tested

non-contrast enhanced abdomen and pelvis MRI

Conditions studied

May-Thurner Syndrome — all drugs for May-Thurner Syndrome →
Iliac Venous Compression — all drugs for Iliac Venous Compression →

Sponsor

Ningcheng Peter Li

Who can join

Adults 18 to 89, any sex, with May-Thurner Syndrome or Iliac Venous Compression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to quantitatively characterize the flow in the pelvic venous structures using 2D and 4D flow MRI with the objective of establishing physiologic and pathologic parameters for downstream computational fluid dynamics analysis. Arm 1: To establish the baseline flow characteristics of the iliac veins in patients with no imaging evidence of iliac venous disease. Arm 2: To assess the flow characteristics of the iliac veins in patients with left iliac vein compression syndrome (a.k.a. May-Thurner syndrome). Arm 3: To assess the flow characteristics of the iliac veins in patients status post iliac stent placement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for May-Thurner Syndrome

Currently open trials in the same condition.

NCT04067505 — Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study · Phase 3 · recruiting
NCT05628948 — Vascular Lab Resource (VLR) Biorepository · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06888024 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ningcheng Peter Li
Last refreshed: 24 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06888024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing